MicroRNAs in cancer therapy: From bench to bedside

Current Cancer Therapy Reviews

Volumn 6, Issue 2, 2010, Pages 157-162

  Sengupta, Srikumar ^a   Bishayee, Anupam ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Antagomir; Antimir; Cancer treatment; Microrna; Mirna; Mirna therapy; Oncomir

Indexed keywords

CURCUMIN; ELLAGITANNIN; EPIGALLOCATECHIN GALLATE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE 11; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; RAS PROTEIN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION; GENE TARGETING; GLIOBLASTOMA; HUMAN; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

EID: 77952946953     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339410791202501     Document Type: Article

References (76)

1. American Cancer Society. Cancer facts and figures 2009. American Cancer Society, Atlanta, 2009.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
3. Cullen BR. Transcription and processing of human microRNA precursors. Mol Cell 2004; 16: 861-5.
4. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902-10.
5. Du T, Zamore PD. MicroPrimer: the biogenesis and function of microRNA. Development 2005; 132: 4645-52.
6. Filipowicz W. RNAi: the nuts and bolts of the RISC machine. Cell 2005; 122: 17-20.
7. Yekta S, Shih IH, Bartel DP. MicroRNA-directed cleavage of HOXB8 mRNA. Science 2004; 304: 594-6.
8. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005; 122: 553-63.
9. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA 2006; 103: 4034-9.
10. Humphreys DT, Westman BJ, Martin DI, Preiss T. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci USA 2005; 102: 16961-6.
11. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
12. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115: 787-98.
13. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res 2004; 32: D109-D111.
14. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33: e179.
15. Sengupta S, den Boon JA, Chen IH, et al. MicroRNA 29c is downregulated in nasopharyngeal carcinomas, up-regulating mRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA 2008; 105: 5874-8.
16. Morin RD, O'Connor MD, Griffith M, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18: 610-21.
17. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1-12.
18. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
19. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell 2007; 27: 91-105.
20. Krek A, Grün D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet 2005; 37: 495-500.
21. Zhang B, Farwell MA. microRNAs: a new emerging class of players for disease diagnostics and gene therapy. J Cell Mol Med 2008; 12: 3-21.
22. Dalmay T. MicroRNAs and cancer. J Intern Med 2008; 263: 366-75.
23. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.
24. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008; 14: 1271-7.
25. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005; 120: 635-47.
26. Hayashita Y, Osada H, Tatematsu Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005; 65: 9628-32.
27. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33.
28. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. C-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-43.
29. Field SJ, Tsai FY, Kuo F, et al. E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell 1996; 85: 549-61.
30. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-81.
31. Galardi S, Mercatelli N, Giorda E, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007; 282: 23716-24.
32. le Sage C, Nagel R, Egan DA, et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-708.
33. Medina R, Zaidi SK, Liu CG, et al. MicroRNAs 221 and 222 by-pass quiescence and compromise cell survival. Cancer Res 2008; 68: 2773-80.
34. Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer 2007; 14: 791-8.
35. Felicetti F, Errico MC, Bottero L, et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008; 68: 2745-54.
36. Fornari F, Gramantieri L, Ferracin M, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene 2008; 27: 5651-61.
37. Zhang C, Kang C, You Y, et al. Co-suppression of miR-221/222 cluster suppresses human glioma cell growth by targeting p27kip1 in vitro and in vivo. Int J Oncol 2009; 34: 1653-60.
38. Faraoni I, Antonetti FR, Cardone J, et al. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792: 497-505.
39. Ovcharenko D, Kelnar K, Johnson C, et al. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res 2007; 67: 10782-8.
40. Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007; 104: 16170-5.
41. Esquela-Kerscher A, Trang P, Wiggins JF, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008; 7: 759-64.
42. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007; 26: 5017-22.
43. Wei JS, Song YK, Durinck S, et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204-13.
44. Tazawa H, Tsuchiya N, Izumiya, M et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-77.
45. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-6.
46. Yan D, Zhou X, Chen X, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 2009; 50: 1559-65.
47. Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 2009; 275: 44-53.
48. Sun F, Fu H, Liu Q, et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett 2008; 582: 1564-8.
49. Tsai WC, Hsu PW, Lai TC, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 2009; 49: 1571-582.
50. Johnson CD, Esquela-Kerscher A, Stefani G, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67: 7713-22.
51. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007; 315: 1576-79.
52. Sampson VB, Rong NH, Han J, et al. MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007; 67: 9762-70.
53. Available from: http://www.mirnatherapeutics.com/ [accessed on April 15, 2009].
54. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 2008; 68: 8164-72.
55. Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochem Soc Trans 2009; 37: 918-25.
56. Stenvang J, Silahtaroglu AN, Lindow M, Elmen J, Kauppinen S. The utility of LNA in microRNA-based cancer diagnostics and therapeutics. Semin Cancer Biol 2008; 18: 89-102.
57. Grünweller A, Hartmann RK. Locked nucleic acid oligonucleotides: the next generation of antisense agents? Biodrugs 2007; 21: 235-43.
58. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65: 6029-33.
59. Linsley PS, Schelter J, Burchard J, et al. Transcripts targeted by the microRNA-16 family cooperatively regulate cell cycle progression. Mol Cell Biol 2007; 27: 2240-52.
60. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007; 67: 8994-9000.
61. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-803.
62. Available from: http://www.santaris.com/ [accessed: September 9, 2009].
63. Torrisani J, Bournet B, du Rieu MC, et al. Let-7 microRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20: 831-44.
64. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009; 48: 1378-98.
65. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441: 111-4.
66. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell 2005; 123: 1133-46.
67. Davis CD, Ross SA. Evidence for dietary regulation of microRNA expression in cancer cells. Nutr Rev 2008; 66: 477-82.
68. Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671-8.
69. Gaedicke S, Zhang X, Schmelzer C, et al. Vitamin E dependent microRNA regulation in rat liver. FEBS Lett 2008; 582: 3542-6.
70. Tsang WP, Kwok TT. Epigallocatechin gallate up-regulation of miR-16 and induction of apoptosis in human cancer cells. J Nutr Biochem 2009; J Nutr Biochem 2010; 21: 140-6.
71. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 2008; 7: 464-73.
72. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002; 2: 740-9.
73. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer 2005; 41: 2438-48.
74. Holst F, Stahl PR, Ruiz C, et al. Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 2007; 39: 655-60.
75. Lall S, Grün D, Krek A, et al. A genome-wide map of conserved microRNA targets in C. elegans. Curr Biol 2006; 16: 460-71.
76. Wen XY, Wu SY, Li ZQ, et al. Ellagitannin (BJA3121), an antiproliferative natural polyphenol compound, can regulate the expression of miRNAs in HepG2 cancer cells. Phytother Res 2009; 23: 778-84.